| Abstract |
【Abstract】Objective To investigate the effects of berberine combined with agomelatine on cognitive function and serum levels of brain-derived neurotrophic factor (BDNF) and interleukin-1β (IL-1β) in patients with schizophrenia (SZ).Methods A total of 80 SZ patients diagnosed and treated in our hospital from June 2020 to June 2023 were selected and investigated, and randomly divided into observation group (Berberine + agomelatine + risperidone, 40 cases) and control group (agomelatine + risperidone, 40 cases).The positive and negative Symptom Scale (PANSS) scores and Montreal Cognitive Assessment Scale (MoCA) scores were recorded in the two groups. Serum BDNF and IL-1β levels were detected in the two groups, and adverse reactions were observed in the two groups.Results After treatment, the scores of positive, negative and psychiatric symptoms in the two groups were significantly decreased compared with those before treatment, and the data in the observation group was lower (P<0.05).MoCA score of the two groups after treatment was significantly higher than that before treatment, and the observation group was higher (P<0.05).After treatment, the level of BDNF in the two groups was significantly increased, and the level of IL-1β was significantly decreased, and the level of BDNF in the observation group was higher, and the level of IL-1β was lower (P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups (continuity correction χ2=0.392, P=0.531).Conclusion Berberine combined with Agomelatine can effectively relieve symptoms of SZ patients, improve cognitive function, regulate serum BDNF, IL-1β levels, and have high safety.
|